LUNG CANCER DIAGNOSTIC AND SCREENING MARKET ANALYSIS

Market News

Global Lung Cancer Diagnostic and Screening Market: Key Developments

• On October 9, 2023, DELFI Diagnostics, a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, announced the initial commercial introduction of FirstLook Lung. FirstLook is a blood test that offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT), with a negative predictive value (NPV) of 99.7 percent.
• On August 2023, LUNGevity Foundation, a leading lung cancer-focused nonprofit organization, announced the launch of its Early Lung Cancer Center (ELCC). The ELCC was created to accelerate the development and broad adoption of early detection and treatment options so people diagnosed with lung cancer have the best chance for long-term survival and a better quality of life.
• In May 2022, DELFI Diagnostics, a pioneering developer of next-generation high-performance, affordable liquid biopsy tests for early cancer detection, announced that it had enrolled the first participants in the CASCADE-LUNG study. CASCADE-LUNG is a prospective, multi-center trial that will enroll up to 15,000 participants at the time of their low dose CT (LDCT) lung cancer screening and will add to the clinical validation of Delfi's liquid biopsy test for lung cancer detection.
• In January 2020, Amgen Inc., a multinational biopharmaceutical company announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510. AMG 510 is the first KRASG12C inhibitor to advance to the clinic for investigation in treatment of multiple tumor types. KRAS G12C is one of the most frequently mutated oncogenes in human cancer. The agreements with both companies will initially focus on CDx tests for non-small cell lung cancer (NSCLC).